Eli Lilly to build new $6.5 billion orforglipron manufacturing facility in Texas
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Encouraging early detection and breaking the silence around men’s health
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
Subscribe To Our Newsletter & Stay Updated